


Scheme 1 Synthesis of *D*-*myo*-inositol 1,4,5-tris(dihydrogen phosphate) [All = allyl, Bn = benzyl]. *Reagents and conditions*: i, 1-ethoxycyclohexene, PTSA; ii, BnCl, NaH, DMF; iii, ethylene glycol, PTSA; iv, AllBr, NaH, DMF; v, aq. AcOH; (a) *l*-menthoxyacetyl chloride, pyridine, (b) separation of diastereoisomers by SiO₂ chromatography or crystallization, (c) Aq. NaOH, MeOH; viii, (a) RhCl(PPh₃)₃, DABCO, (b) HCl, MeOH; ix (for **12a**), **22**, DMAP, pyridine; x (for **12b**), BuLi, **28**; xi (for **12c**), (a) **30**, tetrazole, (b) MCPBA; xii (**12a** to **1**), (a) isopentyl nitrite, (b) H₂, 5% Pd-C; xiii (**12b** or **12c** to **1**), H₂, 5% Pd-C



Scheme 2 Recycle of by-products for preparation of **4a**


published, *l*-menthoxyacetic esters were utilized for optical resolution of some inositol derivatives by other laboratories.^{4f,10} Consequently, derivatization to diastereoisomeric menthoxyacetates is a useful tool for optical resolution of racemic inositols, especially of 1,2-diol derivatives. Camphanic ester was introduced successfully for resolution of inositols by Gigg *et al.*,¹¹ Billington *et al.*¹² and Vacca *et al.*,^{4c} and many inositol derivatives so far have been resolved by this procedure. According to our experiments, however, 1-*O*-(*l*-menthoxyacetyl)-*myo*-inositols derived from 1,2-diols gave better results than did the corresponding camphanate esters. van Boom and co-workers also reported similar results in the synthesis of optically active InsP₃ and *myo*-inositol 1,3,4,5-tetrakis(dihydrogen phosphate).^{4f}

The absolute configuration of 1L-8 was confirmed by transforming it into 1L-1,4,5,6-tetra-*O*-benzyl-*myo*-inositol **17**. Thus

1L-8 was deallylated by isomerization of the double bond [RhCl(PPh₃)₃, diazabicycloundecane (DABCO)] and subsequent acidic methanolysis¹³ to afford dibenzyl ether **15**. The ether **15** was then converted into the dicyclohexylidene derivative 1L-5 as described above for the synthesis of compound **4a**, which was then converted selectively into 4,5-diol 1D-6 {[α]_D²⁰ +33.0}.* Benzylation of 4,5-diol 1D-6 followed by acidic hydrolysis gave 1L-1,4,5,6-tetra-*O*-benzyl-*myo*-inositol **17**. Comparison of its optical rotation {[α]_D²⁰ -22.3} with those⁸ reported for authentic **17** {for example,^{8a} [α]_D²⁰ -24.3} elucidated the stereochemistry of our product **17**.


1L-5,6-Di-*O*-allyl-1,4-di-*O*-benzyl-*myo*-inositol 1L-8 thus resolved was then treated with allyl bromide in the presence of sodium hydroxide in boiling benzene¹⁴ to give the 3-allyl

* The opposite enantiomer was reported to have [α]_D²⁰ +37.0 (c 0.5, CHCl₃). Its value should read -37.0: V. N. Krylova, V. M. Kornitskayer, V. I. Shvets and R. P. Evstigneeva, *Zh. Org. Khim.*, 1975, **11**, 2034.



derivative **9** selectively in 74% yield. After benzylation of compound **9** under standard conditions [NaH, BnCl, dimethylformamide (DMF); 98% yield], removal of the three allyl groups was achieved as described above by isomerization of the double bond and acidic methanolysis¹³ to furnish 1L-1,2,4-tri-*O*-benzyl-*myo*-inositol **11** in 58% yield. Other known deprotection procedures [Bu^tOK, dimethyl sulphoxide (DMSO) then HCl, MeOH:¹⁴ 49% yield and 10% Pd-C, PTSA, aq. MeOH:¹⁵ 24% yield] were less effective. The structure of triol **11** was further supported by transformation into the triacetate and its NMR analysis. After we had completed the synthesis of optically active triol **11**, Gigg *et al.*¹⁶ reported a synthesis of racemic triol **11** which was synthesized by a similar route. They have subsequently described improved routes and the preparation of the opposite enantiomer of compound **11**.¹¹ Very recently, Sato *et al.* also prepared optically active triol **11** by using a chiral starting material, D-glucose.¹⁷

Strategies for the Phosphorylation of myo-Inositols. Synthesis of Fully Protected Ins(1,4,5)P₃.—As reported by several research groups, phosphorylation of inositol derivatives is quite difficult.¹⁸ The reasons are as follows: (i) The reactivity of hydroxy functions in inositols is generally low compared with that of common alcohols and nucleotides because of their steric crowding and hydrogen bonding; (ii) intramolecular transesterification of a monophosphorylated intermediate **19** in the phosphorylation of 1,2-diol **18** occurs preferentially, forming the five-membered cyclic phosphate **21** instead of further phosphorylation of the remaining vicinal hydroxy function leading to bis(phosphate) **20** (Scheme 4).¹⁸



Scheme 4 Diphosphate formation *vs* internal ester exchange in the phosphorylation of 1,2-diol


After some unsuccessful experiments, we obtained the 1,4,5-tris(phosphate) **12a** in 60%* yield by the reaction of triol **11** with dianilinophosphoric chloride **22**¹⁹ which has previously been utilized for phosphorylation of some inositol deriva-

* Racemic triol **11** was first phosphorylated in 41% yield in a similar manner.



tives.^{18c,20} However, the regioisomeric 2,5,6-tris(phosphate) could not be obtained at all by a similar phosphorylation of 1,3,4-tri-*O*-benzyl-*myo*-inositol **23** and small amounts of a complex mixture of bis- and mono-phosphates were detected in the organic layer. The majority of the products were observed in the alkaline aqueous solution obtained in the work-up procedure. This result suggests that the monophosphate once formed at C-4 or C-5 was converted predominantly into the five-membered cyclic phosphate which was then easily hydrolysed²¹ to the water-soluble acyclic monophosphate. Therefore, reactivity of the phosphoryl chloride **22** toward inositol derivatives is too low, and prolonged reaction time sometimes causes serious side reactions. Consequently, we turned our attention to an alternative phosphorylating agent.


For the construction of 1,2-bis(phosphate) functionality, we reported the stepwise phosphorylation procedure^{9b} which involved temporary protection of one of two vicinal hydroxy groups by the laevulinyl function as substrate **24** and employment of phosphorus trichloride (Scheme 5). In order to avoid the use of such a protecting group, we envisaged that a monoalkoxide **26** might be functionally equivalent to the mono-laevulinate **24** and react with one mol equivalent of a phosphorylating agent to give the corresponding monophosphate, such as **27**. We chose tetrabenzyl pyrophosphate **28**²² since



Scheme 5 Laevulinyl route and an alternative for phosphorylation of 1,2-diol. Reagents: i, PCl₃; ii, BnOH; iii, Bu^tOOH

this reagent is an easily handled and fairly stable crystalline compound. Thus, compound **6** was treated with equimolar amounts of butyllithium and the pyrophosphate **28** in tetrahydrofuran (THF) at 0 °C and the bis(phosphate) **29** (26% yield) was unexpectedly isolated, accompanied by half of the starting diol **6** (46% recovery). This result directed us to use two molar equivalents of both reagents. In fact, bis(phosphate) **29** was obtained in 81% yield when 2.1 molar equivalents of butyllithium and 2.5 molar equivalents of pyrophosphate **28** were used. Similar treatment of triol **11** with butyllithium (3.6 mol equiv.) and pyrophosphate **28** (3.7 mol equiv.) gave 1,4,5-tris(phosphate) **12b** in 72% yield (Scheme 1).


Phosphorylation by the activation of an alcohol has been well documented²³ and the method used here has already been employed by Bartlett²⁴ in the synthesis of shikimic acid monophosphate where lithium diisopropylamide (LDA) was used as a base instead of butyllithium. After we had submitted our paper concerning the present phosphorylation method,²⁵ similar procedures, except for the use of sodium hydride and potassium hydride as bases, were employed for the synthesis of



Scheme 6 Phosphorylation of vicinal diol by activation of the hydroxy group. Reagents: i, **28**, BuLi

inositol 1,3,4,5-tetrakis(phosphate)²⁶ and several inositol tris(phosphates).^{4c,27}

Utilization of a highly active phosphorus reagent instead of activation of the alcoholic component in the synthesis of inositol phosphates is useful, as has been demonstrated by a number of groups.²⁸ Among these methods, a phosphoramidite method is especially effective.^{4a,29} We have also recently developed an efficient phosphorylation method which uses a new phosphitylating agent, *o*-xylylene *N,N*-diethylphosphoramidite (**30**, XEPA).³⁰ According to this method, a variety of inositol derivatives as well as other alcohols were smoothly phosphorylated to afford phosphoric esters in high yields. Thus, treatment of triol **11** with XEPA in the presence of tetrazole followed by addition of *m*-chloroperbenzoic acid (MCPBA) afforded tris(phosphate) **12c** in 98% yield (Scheme 1). 2,4,5-Triol **23** was similarly phosphorylated in 87% yield while dianilinophosphoric chloride **22** and pyrophosphate **28** gave the corresponding 2,4,5-triesters in 0 and 45% yield, respectively. Judging from these results, the efficacy of XEPA is now apparent.



Final Deprotection Step in the Synthesis of myo-Inositol 1,4,5-Tris(dihydrogen phosphate).—The final stage of the synthesis of InsP₃ **1** is the removal of protecting groups from the fully protected tris(phosphates) **12**. The anilino-phosphate derivative **12a** was deblocked by a two-step procedure. Firstly, the anilino groups in compound **12a** were removed by treatment with isoamyl (isopentyl) nitrite in a 1:1:1 mixture of acetic anhydride–acetic acid–pyridine,³¹ then subsequent removal of two benzyl groups by hydrogenolysis on 5% Pd–C in aqueous methanol afforded the desired final product **1** in low yield (17% yield from **12a**) accompanied by the 4,5-cyclic pyrophosphate derivative **31** in a similar yield. Cellulose column chromatography effected separation of tris(phosphate) **1** from pyrophosphate **31**. The structure of compound **1** thus isolated as the ammonium salt was confirmed by ¹H, ¹³C and ³¹P NMR spectroscopy and mass spectrum analyses as well as by elemental analysis. In particular, 2D *J*-resolved NMR analysis gave useful information about coupling patterns which suggested the existence of InsP₃ in a typical chair form. The structure of pyrophosphate **31** was supported clearly by ¹H, ¹³C and ³¹P NMR analysis. Observation of resonance peaks at δ_p –9.02 and –8.65 with coupling constant $J_{p,p}$ 17.5 Hz in the ³¹P NMR spectrum suggested the cyclic pyrophosphate structure.³²

In the cases of the two other fully protected 1,4,5-tris(phosphates) **12b** and **12c**, removal of all protecting groups was quite easily accomplished by hydrogenolysis by using 5% Pd–C as catalyst. Simple filtration to remove the catalyst after com-

pletion of the reaction, and evaporation of the aqueous filtrate involving ammonia or pyridine, afforded essentially pure crystalline product as an ammonium or pyridinium salt quantitatively since by-products such as toluene and *o*-xylene were volatile. Thus, hydrogenolytic deprotection made isolation of highly polar InsP₃ **1** easy. Further purification of the ammonium salt was accomplished by recrystallization from aqueous MeOH to afford analytically pure InsP₃ **1** as a crystalline solid in quantitative yield. The pyridinium salt was transformed into the corresponding sodium and potassium salts by passage through a cation-exchange column (Na⁺- and K⁺-forms). It should be noted that ammonium, sodium, and potassium salts of InsP₃ **1** crystallized from aq. MeOH possessed methanol of crystallization as observed in NMR analyses, and which would not be removed even by heating at ~90 °C *in vacuo*. In order to remove the methanol, evaporation of a solution of the crystals in water under reduced pressure was repeated (see Experimental section). Hydrogenolysis in the presence of ammonium acetate or formate (the latter is better because it can be removed during evaporation of the reaction solvents) might be useful for preventing the migration of phosphate functions by the formation of ammonium salts, although such experiments using compound **12b** as substrate on a small scale all gave the same results as did experiments in the absence of the salts. We can now prepare analytically and optically pure *D*-myo-inositol 1,4,5-tris(phosphate) ammonium, sodium and potassium salts as crystalline solids in quantity.

Physical, Spectral and Biological Properties of Compound 1.—

Elemental analysis of the ammonium salt of InsP₃ **1** showed that the number of ammonium ions was 3.5. That of the sodium and potassium cations in the corresponding salts was shown to be 3. All of these salts showed a pH of ~6.5 in aqueous solutions and optical rotations $[\alpha]_D \sim -10$ in water. When the pH of the potassium salt of InsP₃ **1** in water was adjusted to 10.6 by addition of cyclohexylamine, the value of the rotation increased to –25.5, which was similar to those ($[\alpha]_D \sim -30$) obtained at pH ~10 by other groups.^{4j–l} Therefore we suggest that the optical rotation of InsP₃ **1** at higher pH shows a generally higher absolute numerical number than that at neutrality, while Ley *et al.* have recently reported $[\alpha]_D -24$ at pH 6.9.^{4p}

The three kinds of salts (NH₄, Na, K) of InsP₃ **1** showed essentially the same NMR spectra. Mayr and Dietrich³³ have reported a similar ¹H NMR spectrum for the ammonium salt of compound **1** which showed pD 6.03 in D₂O. Most research groups have prepared the hexaammonium and hexasodium salts of InsP₃ **1**, whose aqueous solutions showed pH ~9. Their fully dissociated samples showed partly different ¹H NMR spectra^{4b,j,k} as was observed for the optical rotations. When the pD of an D₂O solution of our neutral sample was brought to ~9 with NaOD, the resulting solution gave identical spectra with those of an alkaline sample.³⁴

Biological evaluation of synthetic InsP₃ **1** was carried out by using InsP₃ 5-phosphatase (erythrocyte ghosts prepared from human blood), InsP₃ 3-kinase (supernatant obtained by homogenizing rat whole brain), binding (rat cerebellum), and Ca²⁺ release (peritoneal macrophage from guinea pig) assays and its biological properties were found to be indistinguishable from those of the natural compound **1**.*

Experimental

General.—NMR spectra (¹H, ¹³C and ³¹P) were recorded on a JEOL JNM-GSX270, JEOL JNM-FX100S or JEOL JNM

* These biological experiments were accomplished by Dr. Masato Hirata of Kyushu University.

GX400 spectrometer. When CDCl_3 was used as the solvent, SiMe_4 (δ_{H} 0.0) for proton spectra and the signal of the solvent (δ_{C} 77.0) for carbon spectra were used as references. When D_2O was used as solvent, the signal of HOD (δ 4.64) was utilized for proton spectra as a standard and dioxane (δ_{C} 67.4) in a D_2O solution for carbon spectra as an external standard. In the case of ^{31}P NMR spectra, 85% H_3PO_4 (δ_{P} 0.0) was used as an external standard and positive chemical shifts are downfield from it. ^{13}C and ^{31}P NMR spectra were all taken under ^1H -decoupled conditions. J -values are given in Hz. IR spectra were recorded on a Hitachi EPI-G3 spectrophotometer. Optical rotations were measured on a Union PM-101 spectrometer, and the units of $[\alpha]_{\text{D}}$ are to be read as 10^{-1} deg $\text{cm}^2 \text{g}^{-1}$. Elemental analyses were performed on a Perkin-Elmer 240C instrument. pH was measured by a Horiba Compact pH Meter C-1. TLC analyses were performed on Merck pre-coated plates, Silica Gel 60 F254. Solvents used for chromatography are abbreviated as follows: EA = AcOEt, H = hexane. Flash chromatography was utilized for column chromatography by using Wako Pure Chemical Industries, silica gel, Wakogel C-300. Cellulose pre-coated TLC plates (SF-2020) were purchased from Funakoshi, and Whatman BioSystems microgranular cellulose powder, CC-31, was used for column chromatography. An anhydrous reaction atmosphere was achieved by nitrogen gas. Anhydrous solvents used here were prepared in the usual manner. Extracts obtained after work-up were dried over MgSO_4 or Na_2SO_4 . Light petroleum refers to the fraction boiling in the range 30–70 °C.

1,2:4,5-Di-O-cyclohexylidene-myo-inositol 4a (Recycling Other Waste Cyclohexylidenated Products).—The mother liquid which was obtained after crystallization of 1,2:4,5-di-O-cyclohexylidene-myo-inositol (19.4 g) produced by the reaction⁵ of myo-inositol (71.5 g) with 1-ethoxycyclohexene (133 g) was subjected to evaporation and the residual mixture was further heated at ~65 °C under reduced pressure to remove volatile materials completely. The residue was dissolved in the solvent system of EtOH, benzene, and light petroleum (1:5:5) (400 cm^3) and the solution was stirred with PTSA· H_2O (1.2 g) at room temperature for 1 h. After neutralization of the solution with Bu^tOK (1.1 g), precipitated crystalline material was collected, and recrystallized from EtOH to give 1,2-O-cyclohexylidene-myo-inositol (56.3 g, m.p. 174–175 °C; lit.,³⁵ 179–180 °C). A DMF (220 cm^3) solution of this compound was treated with 1-ethoxycyclohexene (54.6 g) and PTSA· H_2O (0.65 g) at 95–100 °C for 1.5 h and the resulting mixture was worked up similarly to the procedure described in the literature⁵ to afford title compound **4a** (12.4 g, m.p. 171–172 °C; (lit.,⁵ 172–174 °C).

(±)-1,4-Di-O-benzyl-2,3-O-cyclohexylidene-myo-inositol **6**.—To a solution of 1,4-di-O-benzyl-2,3:5,6-di-O-cyclohexylidene-myo-inositol **5**³⁶ (1.0 g, 1.92 mmol) in CHCl_3 (35 cm^3) were added a CHCl_3 (16 cm^3) solution of ethylene glycol (122 mg, 1.96 mmol) and PTSA (18 mg) and the mixture was stirred at room temperature for 4 h. After addition of aq. K_2CO_3 for neutralization of the solution, the resultant organic layer was washed with water, dried, and concentrated under reduced pressure. The residue was recrystallized from benzene to afford compound **6** (678 mg, 80% yield), R_{f} [EA–H (1:1)] 0.4; m.p. 140–141 °C (lit.,³⁶ 147.6–148 °C).

(±)-4,5-Di-O-allyl-3,6-di-O-benzyl-1,2-O-cyclohexylidene-myo-inositol **7**.—To a solution of compound **6** (2.73 g, 6.20 mmol) in DMF (25 cm^3) was added a 50% mineral oil dispersion of NaH (684 mg, 14.25 mmol) and the mixture was cooled in an ice-bath. After addition of allyl bromide (1.65 g, 13.64 mmol), the resultant mixture was stirred at room temperature for 30 min and diluted with water. The solution

was extracted with ethyl acetate ($\times 3$) and the extracts were washed with water, dried and concentrated under reduced pressure. The residue was chromatographed on silica gel and eluted with EA–H (1:6) to give compound **7** as an oil (3.23 g, quant), R_{f} [EA–H (1:3)] 0.6; ν_{max} (Nujol)/ cm^{-1} 1060, 1030 and 920; δ_{H} (270 MHz; CDCl_3) 3.22 (1 H, dd, $J_{5,6}$ 10.0, $J_{5,4}$ 8.5), 3.59 (1 H, dd, $J_{3,4}$ 8.5, $J_{3,2}$ 3.8), 3.71 (1 H, dd, $J_{6,5}$ 10.0, $J_{6,1}$ 7.0), 3.75 (1 H, dd, $J_{4,3} = J_{4,5} = 8.5$), 4.04 (1 H, dd, $J_{1,6}$ 7.0, $J_{1,2}$ 5.5), 4.23 (1 H, dd, $J_{2,1}$ 5.5, $J_{2,3}$ 3.8), 4.73 and 4.81 (2 H, ABq, J 12.5) and 4.76 and 4.87 (2 H, ABq, J 12.5); δ_{C} (67.8 MHz; CDCl_3) 72.92, 73.59, 73.84 (two unresolvable singlets, 2 C), 76.83, 78.46, 80.32, 81.58, 82.55, 110.14, 116.40, 116.42, 127.26, 127.52, 127.67, 127.69, 128.02, 128.15, 135.07, 135.11, 138.21 and 138.55.

(±)-5,6-Di-O-allyl-1,4-di-O-benzyl-myo-inositol **8**.—A solution of compound **7** (3.23 g, 6.20 mmol) in 80% aq. acetic acid (30 cm^3) was stirred and heated at 100 °C for 5 h. After evaporation of volatile materials under reduced pressure, the residue was chromatographed on silica gel and eluted with EA–H (1:1) to give compound **8** (2.41 g, 88%), R_{f} [EA–H (1:2)] 0.2; m.p. 104.5–106 °C (from benzene–hexane) (lit.,¹⁶ 106–108 °C) (Found: C, 70.8; H, 7.35. Calc. for $\text{C}_{26}\text{H}_{32}\text{O}_6$: C, 70.89; H, 7.32%); ν_{max} (Nujol)/ cm^{-1} 3395, 3300, 1135, 1090, 1060, 1000 and 915; δ_{H} (100 MHz; CDCl_3) 2.44 (2 H, br s), 3.30 (dd, $J_{1,2}$ 2.9, $J_{1,6}$ 9.1), 3.23 (1 H, dd, $J_{5,6} = J_{5,4} = 9.1$), 3.38 (1 H, dd, $J_{3,2}$ 2.9, $J_{3,4}$ 9.1), 3.71 (1 H, dd, $J_{6,5} = J_{6,1} = 9.1$), 3.74 (1 H, dd, $J_{4,3} = J_{4,5} = 9.1$), 4.20 (1 H, dd, $J_{2,1} = J_{2,3} = 2.9$), 4.20–4.30 (4 H, m), 4.67 (2 H, s), 4.69 and 4.94 (2 H, ABq, J 11.4), 5.02–5.42 (4 H, m), 5.70–6.18 (2 H, m) and 7.12–7.40 (10 H, m).

1D-4,5-Di-O-allyl-3,6-di-O-benzyl-1-l-menthoxyacetyl-myo-inositol **14a** and 1L-4,5-Di-O-allyl-3,6-di-O-benzyl-1-l-menthoxyacetyl-myo-inositol **14b**.—To a solution of racemic 1,2-diol **8** (4.66 g, 10.6 mmol) in pyridine (50 cm^3) at 0 °C was added dropwise *l*-menthoxyacetyl chloride (2.59 g, 11.1 mmol) and the reaction mixture was stirred at the temperature for 5 h. After addition of water (100 cm^3) the mixture was extracted with ethyl acetate (~50 $\text{cm}^3 \times 3$) and the extracts were washed sequentially with water, saturated aq. KHSO_4 , saturated aq. NaHCO_3 , and water, and dried. After evaporation of the solvent, the residue was subjected to column chromatography on silica gel [diethyl ether–hexane (1:2)] to give diastereoisomers **14a** (2.64 g, 39%) and **14b** (2.92 g, 43%). When the residue was dissolved in hexane and cooled in an ice-bath, compound **14a** crystallized upon addition of a small amount of pure crystalline **14a** as seeds (m.p. 63–66 °C, ~2.0 g from 4.5 g of **8**). However, crystallization from the reaction mixture was not always successful. **Compound 14a**: R_{f} [EA–H (3:2)] 0.52; m.p. 67.5–68.5 °C (from hexane) (Found: C, 71.9; H, 8.0. $\text{C}_{38}\text{H}_{52}\text{O}_8$ requires C, 71.67; H, 8.23%); $[\alpha]_{\text{D}}^{20} -54.1$ (c 2.2, CHCl_3); ν_{max} (CHCl_3)/ cm^{-1} 3450 and 1750; δ_{H} (270 MHz; CDCl_3) 0.79 (3 H, d, J 6.7), 0.90 (6 H, d, J 6.7), 1.26 (2 H, m), 1.62 (2 H, m), 2.05 (1 H, m), 2.30 (1 H, m), 2.48 (1 H, br s), 3.13 (1 H, ddd, J 10.4, 10.4 and 3.9), 3.32 (1 H, dd, $J_{5,4} = J_{5,6} = 9.5$), 3.42 (1 H, dd, $J_{3,4}$ 9.5, $J_{3,2}$ 2.7), 3.73 (1 H, dd, $J_{4,3} = J_{4,5} = 9.5$), 3.94 and 4.18 (2 H, ABq, J 16.7), 3.95 (1 H, dd, $J_{6,1} = J_{6,5} = 9.5$), 4.23 (1 H, dd, $J_{2,1} = J_{2,3} = 2.7$), 4.32 (4 H, m), 4.63 and 4.69 (2 H, ABq, J 11.3), 4.65 and 4.83 (2 H, ABq, J 11.3), 4.84 (1 H, dd, $J_{1,6}$ 9.5, $J_{1,2}$ 2.7), ~5.21 (4 H, complex) and 5.98 (2 H, m); δ_{C} (67.8 MHz; CDCl_3) 16.23, 20.92, 22.22, 23.18, 25.38, 31.31, 34.28, 39.69, 48.04, 65.19, 67.89, 72.91, 73.16, 74.52, 75.47, 78.79, 79.43, 79.76, 80.59, 82.52, 116.62, 116.74, 127.41, 127.49, 127.77, 127.95, 128.25, 128.45, 134.99, 135.10, 137.48, 138.52 and 170.22.

Diastereoisomer **14b**: R_{f} [EA–H (3:2)] 0.61; $[\alpha]_{\text{D}}^{20} -14.7$ (c 1.9, CHCl_3); ν_{max} (CHCl_3)/ cm^{-1} 3450 and 1750; δ_{H} (100 MHz; CDCl_3) 3.20 (1 H, dd, $J_{5,4} = J_{5,6} = 8.3$), 3.32 (1 H, dd, $J_{3,2}$ 2.5, $J_{3,4}$ 8.3), 3.62 (1 H, dd, $J_{4,3} = J_{4,5} = 8.3$), 3.83 (1 H, dd, $J_{6,1} = J_{6,5} = 8.3$), 3.83 and 4.01 (2 H, ABq, J 15.8), 4.02–4.24 (H_2 and

4 H, m), 4.35–4.79 (4 H, m), 4.69 (1 H, dd, $J_{1,2}$ 2.5, $J_{1,6}$ 8.3), 4.88–5.24 (4 H, m) and 5.54–5.98 (2 H, m).

1L-5,6-Di-O-allyl-1,4-di-O-benzyl-myo-inositol 1L-8.—To a solution of compound **14a** (5.92 g, 9.3 mmol) in methanol (50 cm³) was added 2.5 mol dm⁻³ NaOH (4.46 cm³) and the mixture was stirred at room temperature overnight. After addition of water (100 cm³), the solution was extracted with ethyl acetate (70 cm³ × 3) and the extracts were washed successively with aq. NaHCO₃ (30 cm³), water (50 cm³), and brine (50 cm³), and dried. After evaporation of the solvent, the residue was recrystallized from benzene–hexane to give the title compound **1L-8** (4.01 g, 98%), R_f [EA–H (1:6)] 0.2; m.p. 105–106 °C (from benzene–hexane); $[\alpha]_D^{16}$ –14.3 (c 1.3, CHCl₃). The same IR and ¹H NMR spectra were obtained as from racemic **8**.

1D-5,6-Di-O-allyl-1,4-di-O-benzyl-myo-inositol 1D-8.—The title compound (1.85 g, 99%) was similarly obtained by treatment of compound **14b** (2.72 g, 4.27 mmol) in methanol (30 cm³) with 2.5 mol dm⁻³ NaOH (2.05 cm³) at room temperature for 5 h, m.p. 105–106 °C (from benzene–hexane); $[\alpha]_D^{16}$ +14.2 (c 1.3, CHCl₃). The same IR and ¹H NMR spectra were obtained as for racemic **8**.

Elucidation of the Absolute Configuration of 1L-8.—1,2-Diol **1L-8** was first transformed into 1L-1,4-di-O-benzyl-2,3-O-cyclohexylidene-myo-inositol **1L-6** via optically active dibenzyl ether **15** and the subsequent 1,2:4,5-di-O-cyclohexylidene derivative **1D-5** which were briefly characterized by ¹H NMR spectroscopy. A mixture of compound **1D-5** (182 mg, 0.35 mmol), ethylene glycol (22 mg) and PTSA–H₂O (3.3 mg) in anhydrous CHCl₃ (obtained by passage through basic Al₂O₃; Merck No. 1076) was stirred at room temperature for 4 h and K₂CO₃ was added for neutralization. The organic phase was washed with water, and silica gel column chromatography and then recrystallization from anhydrous ethanol gave **1L-6** (117 mg, 76%), m.p. 119 °C; $[\alpha]_D^{20}$ +33.0 (c 0.5, CHCl₃) {lit. (for the opposite enantiomer),* m.p. 142–143 °C; $[\alpha]_D^{20}$ –37.0, for sign of the rotation see footnote*} (Found: C, 70.7; H, 7.4. Calc. for C₂₆H₃₂O₆: C, 70.89; H, 7.32%). The ¹H NMR spectrum (100 MHz) was superposable on that of racemic **6**. To a solution of **1L-6** (115 mg, 0.26 mmol) in DMF (5 cm³) was added a 50% mineral oil dispersion of NaH (28 mg, 0.57 mmol) and benzyl chloride (69 mg, 0.55 mmol), and the mixture was stirred at room temperature for 2 h. After careful addition of water, extraction with diethyl ether was carried out and the ethereal solution was washed successively with water and brine, dried, and evaporated under reduced pressure.

The residual product **16** was dissolved in 80% aq. AcOH and the solution was heated at 90–100 °C for 2 h. Volatile materials were distilled off under reduced pressure and silica gel column chromatography [EA–H (1:1)] and subsequent recrystallization from methanol gave 1L-4,5,6-tetra-O-benzyl-myo-inositol **17** (87 mg, 60%), m.p. 139–140 °C; $[\alpha]_D^{20}$ –22.3 (c 1.3, CHCl₃) {lit.^{8a} m.p. 141–143 °C; $[\alpha]_D^{20}$ –24.3 (c 1.3, CHCl₃); for other reported m.p. and optical rotation data for **17** see reference 8b} (Found: C, 75.3; H, 6.7. Calc. for C₃₄H₃₆O₆: C, 75.53; H, 6.71%).

1D-1,4,5-tri-O-allyl-3,6-di-O-benzyl-myo-inositol 9.—A mixture of **1L-8** (721 mg, 1.64 mmol), allyl bromide (297 mg, 2.46 mmol), powdered NaOH (883 mg, 13.5 mol equiv.), and anhydrous benzene (16 cm³) was heated under reflux for 80 min. After being cooled, the reaction mixture was washed with water (× 2), dried, and evaporated. Column chromatography of the residue [SiO₂; EA–H (1:4)] yielded triallyl derivative **9** as an oil

(612 mg, 78%), R_f [EA–H (1:3)] 0.3; $[\alpha]_D^{30}$ +3.1 (c 1.6, CHCl₃); ν_{\max} (neat)/cm⁻¹ 3450, 1060, 990 and 920; δ_H (100 MHz; CDCl₃) 2.42 (1 H, br s), 3.19 (1 H, dd, $J_{3,2}$ 2.3, $J_{3,4}$ 9.1), 3.20 (1 H, dd, $J_{5,4}$ = $J_{5,6}$ = 9.1), 3.26 (1 H, dd, $J_{1,2}$ 2.3, $J_{1,6}$ 9.1), 3.76 (1 H, dd, $J_{4,5}$ = $J_{4,3}$ = 9.1) and 3.82 (1 H, dd, $J_{6,5}$ = $J_{6,1}$ = 9.1).

1D-1,4,5-Tri-O-allyl-2,3,6-tri-O-benzyl-myo-inositol 10.—A mixture of compound **9** (1.57 g, 3.26 mmol), a 50% mineral oil dispersion of NaH (188 mg, 3.92 mmol), and anhydrous DMF (32 cm³) was stirred for 10 min and benzyl chloride (454 mg, 3.58 mmol) was added. After the mixture had been stirred at room temperature for 1 h, water was added and the mixture was extracted with ethyl acetate (× 2). The extracts were washed with water, dried, and evaporated. The residue was chromatographed on silica gel [EA–H (1:7)] to afford compound **10** as an oil (1.85 g, 99%), R_f [EA–H (1:7)] 0.5; $[\alpha]_D^{30}$ –2.5 (c 1.6, CHCl₃); ν_{\max} (neat)/cm⁻¹ 1065, 985 and 920; δ_H (270 MHz; CDCl₃) 3.19 (1 H, dd, $J_{3,4}$ 9.5, $J_{3,2}$ 2.4), 3.25 (1 H, dd, $J_{5,4}$ = $J_{5,6}$ = 9.5), 3.26 (1 H, dd, $J_{1,6}$ 9.5, $J_{1,2}$ 2.4), 3.87 (1 H, dd, $J_{6,1}$ = $J_{6,5}$ = 9.5), 3.93 (1 H, dd, $J_{4,3}$ = $J_{4,5}$ = 9.5), 3.97 (1 H, dd, $J_{2,1}$ = $J_{2,3}$ = 2.4), 4.07 (2 H, m), 4.34 (4 H, m), 4.57 and 4.67 (2 H, ABq, J 11.9), 4.77 and 4.85 (2 H, ABq, J 10.3) and 4.85 (2 H, s); δ_C (67.8 MHz; CDCl₃) 71.56, 72.78, 73.89, 74.33, 74.47, 74.53, 75.79, 80.41, 80.55, 81.29, 81.47, 83.18, 116.41, 116.47, 116.52, 127.21, 127.39, 127.47, 127.50, 127.54, 127.57, 127.61, 127.73, 128.01, 128.05, 128.10, 128.13, 128.21, 128.25, 128.27, 128.39, 128.90, 129.66, 134.86, 135.36, 135.41, 138.47, 138.84 and 138.89.

1L-1,2,4-Tri-O-benzyl-myo-inositol 11.—1D-1,4,5-Tri-O-allyl-2,3,6-tri-O-benzyl-myo-inositol **10** (102 mg, 0.179 mmol), tris-(triphenylphosphine)rhodium(i) chloride (34 mg, 0.037 mmol), 1,4-diazabicyclo[2.2.2]octane (DABCO) (12.4 mg, 0.111 mmol), and 90% aq. ethanol (2 cm³) were heated together under reflux for 8 h and the mixture was diluted with water. The solution was extracted twice with ethyl acetate and the combined extracts were washed with water, dried, and then concentrated to dryness under reduced pressure. The residue was heated under reflux for 20 min with 0.1 mol dm⁻³ methanolic hydrogen chloride (2 cm³) which was prepared from acetyl chloride and anhydrous methanol. After saturated aq. NaHCO₃ had been added to neutralize the reaction mixture, the resultant solution was extracted twice with ethyl acetate and the extracts were washed with water, dried, and then condensed under reduced pressure. The residue was chromatographed on silica gel [EA–H (1:1)] to give the title compound **11** (48 mg, 59%), R_f [EA–H (1:1)] 0.2; m.p. 117–119 °C (from EtOH); $[\alpha]_D^{16}$ +15.5 (c 1, CHCl₃) {lit.¹⁷ m.p. 117–119 °C; $[\alpha]_D$ +12.4; lit. (for the opposite enantiomer),¹¹ m.p. 118–120 °C; $[\alpha]_D^{25}$ –9.0} (Found: C, 72.15; H, 6.80. Calc. for C₂₇H₃₀O₆: C, 71.98; H, 6.71%); ν_{\max} (Nujol)/cm⁻¹ 3460 and 3350; δ_H (270 MHz; CDCl₃) 2.37 (1 H, br d, J 6.1), 2.75 (2 H, br s), 3.27 (1 H, dd, $J_{1,6}$ 9.8, $J_{1,2}$ 2.4), 3.45 (1 H, dd, J_5 = $J_{5,6}$ = 9.2), 3.50 (1 H, m), 3.67 (1 H, dd, $J_{4,3}$ = $J_{4,5}$ = 9.2), 4.00 (1 H, dd, $J_{6,1}$ = $J_{6,5}$ = 9.2), 4.06 (1 H, dd, $J_{2,1}$ = $J_{2,3}$ = 2.4), 4.56 and 4.67 (2 H, ABq, J 11.8), 4.70 and 4.88 (2 H, ABq, J 11.9) and 4.82 and 4.92 (2 H, ABq, J 11.5); δ_C (67.8 MHz; CDCl₃–D₂O) 72.32, 72.39, 72.45, 74.64, 74.70, 75.01, 76.28, 80.14, 81.60, 127.72, 127.80 (2 C), 127.85, 128.00, 128.06, 128.39, 128.53, 128.56, 137.62, 138.44 and 138.51.

(±)-1,4,5-Tri-O-acetyl-2,3,6-tri-O-benzyl-myo-inositol.—The usual acetylation procedure using racemic triol **11** (23.6 mg, 0.052 mmol) and an excess of acetic anhydride in pyridine gave the title triacetate (27.5 mg, 91%; R_f [EA–H (1:3)] 0.7; m.p. 116.5–117 °C (from EtOH) (lit.³⁷ 123–125 °C) (Found: C, 68.35; H, 6.3. Calc. for C₃₃H₃₆O₉: C, 68.72; H, 6.29%); ν_{\max} (Nujol)/cm⁻¹ 1735, 1100, 1040 and 1020; δ_H (100 MHz; CDCl₃) 1.91 (6 H, s), 1.98 (3 H, s), 3.54 (1 H, dd, $H_{3,2}$ 2.8, $J_{3,4}$ 10.5), 4.11 (1 H, dd, $J_{2,1}$ = $J_{2,3}$ = 2.8), 4.11 (1 H, dd, $J_{6,1}$ = $J_{6,5}$

* See footnote on page 730.

10.5), 4.46 and 4.85 (2 H, ABq, J 12), 4.60 and 4.64 (2 H, ABq, J 4), 4.74 (1 H, dd, $J_{1,2}$ 2.8, $J_{1,6}$ 10.5), 5.04 (1 H, dd, $J_{5,4} = J_{5,6} = 10.5$) and 5.53 (1 H, dd, $J_{4,3} = J_{4,5} = 10.5$).

1L-1,2,4-Tri-*O*-benzyl-3,5,6-tris-*O*-dianilinophosphoryl-*myo*-inositol 12a.—To a solution of triol 1L-11 (855 mg, 1.90 mmol) in pyridine (6.0 cm³) at -10 °C was added a solution of dianilinophosphoric chloride (7.08 g, 26.6 mmol) in pyridine (26 cm³) and a catalytic amount of 4-(dimethylamino)pyridine and the resulting solution was stirred at room temperature for 2 days. After addition of 5% aq. potassium acetate (48 cm³), the resultant solution was stirred at room temperature for 30 min and extracted with chloroform (\times 2). The extracts were washed successively with 20% aq. KHSO₄ and water, dried, and concentrated to dryness. The residue was subjected to silica gel column chromatography with a 10:1 mixture of methylene dichloride and acetone to give fractions containing the desired product [R_f [CHCl₃-MeOH (30:1)] 0.25] and an impurity (R_f 0.20). The combined eluates were again chromatographed on silica gel [CHCl₃-MeOH (30:1)] to give almost pure compound 12a (1.30 g, ~60%), which was recrystallized from ethanol-hexane to afford crystals with m.p. 225–227 °C. This product was again recrystallized from benzene to give the product of m.p. 227–229 °C which still involved a trace of impurity, v_{\max} (Nujol)/cm⁻¹ 3400, 3125, 1210 and 1030; δ_p (40.5 MHz; C₅D₅N; Instrument: JEOL PS-100) 1.816 (1 P) and 2.930 (2 P); δ_H (100 MHz; CDCl₃) complex; m/z (FD. Instrument: JEOL JMS-D300) 1141 [(M + H)⁺].

1L-1,2,4-Tri-*O*-benzyl-3,5,6-tris-*O*-dibenzoyloxyphosphoryl-*myo*-inositol 12b.—Butyllithium (1.57 Mol dm⁻³ in hexane; 5.8 cm³, 9.11 mmol) and tetrabenzyl pyrophosphate 28 (5.11 g, 9.49 mmol) were successively added to a solution of 1L-1,2,4-tri-*O*-benzyl-*myo*-inositol (1.14 g, 2.53 mmol) in THF (30 cm³) at -78 °C and the resulting solution was cooled to 0 °C by an ice-salt-water-bath and stirred for 1 h. Precipitated lithium dibenzyl phosphate was filtered off, and washed with diethyl ether, and the combined filtrate and washings were washed with water, dried and evaporated to dryness. The residue was subjected to flash column chromatography to afford the *title compound* (2.30 g, 72%), recrystallization of which (H-EA) gave analytically pure crystals, m.p. 109–110 °C (Found: C, 67.05; H, 5.8. C₆₉H₆₉O₁₅P₃ requires C, 67.31; H, 5.65%); $[\alpha]_D^{25}$ -5.3 (c 1.7, CHCl₃); v_{\max} (Nujol)/cm⁻¹ 1260 and 1000; δ_H (270 MHz; CDCl₃) 3.45 (1 H, dd, $J_{1,6}$ 10.1, $J_{1,2}$ 2.1), 4.10 (1 H, dd, $J_{4,3} = J_{4,5} = 9.5$), 4.25 (1 H, ddd, $J_{3,4}$ 9.5, $J_{3,P3}$ 7.5, $J_{3,2}$ 2.1), 4.33 (1 H, dd, $J_{2,1} = J_{2,3} = 2.1$), 4.53 (1 H, ddd, $J_{5,4} = J_{5,6} = J_{5,P5} = 9.5$), 4.40–5.10 (19 H, complex, benzylic protons and 4 H) and 6.80–7.35 (45 H, m); δ_C (67.8 MHz; CDCl₃) 69.10 (d, J 4.9), 69.16 (d, J 4.9), 69.31 (d, J 5.5), 69.40 (d, J 6.1), 69.44 (d, J 4.9), 69.49 (d, J 6.1), 72.25, 74.56, 75.09, 75.22, 77.21, 77.75, 77.88, 77.90 (m), 77.97, 79.00 (m), 127.14, 127.57, 127.66, 127.74, 127.79, 127.82, 127.84, 128.03, 128.05, 128.07, 128.24, 128.27, 128.33, 128.51, 128.54, 135.47 (d, J 7.3), 135.50 (d, J 6.7), 135.76 (d, J 6.7), 136.06 (d, J 8.0), 136.07 (d, J 7.3), 136.09 (d, J 7.3), 137.30, 138.18 and 138.20; δ_p (109 MHz; CDCl₃) -1.32, -1.08 and -0.93.

1L-1,2,4-Tri-*O*-benzyl-3,5,6-tris-*O*-(*o*-xylylenedioxyphosphoryl)-*myo*-inositol 12c.—To a suspension of 1L-1,2,4-tri-*O*-benzyl-*myo*-inositol 11 (0.85 g, 1.89 mmol) and 1*H*-tetrazole (0.94 g, 13.45 mmol) in methylene dichloride (19 cm³) was added *o*-xylylene *N,N*-diethylphosphoramidite 30 (2.16 g, 9.01 mmol) at room temperature and the resulting clear solution was stirred for 10 min. Water (0.65 cm³) was added and the mixture was stirred for an additional 10 min to destroy an excess of the amidite, the mixture was then cooled to -40 °C. MCPBA (2.83 g, 16.37 mmol) was added to the solution and the cooling bath was removed. After being stirred for 10 min, the solution was

diluted with ethyl acetate and the organic layer was washed successively with 10% aq. Na₂SO₃, saturated aq. NaHCO₃, water, and brine, and then dried. The reaction mixture was chromatographed on silica gel [Et₂O-CHCl₃ (1:5), R_f 0.31] to give *tris*(phosphate) 12c (1.83 g, 97%), m.p. 101–103 °C (from EA-H) (Found: C, 61.1; H, 5.4; P, 9.55. C₅₁H₅₁O₁₅P₃ requires C, 61.45; H, 5.16; P, 9.32%); $[\alpha]_D^{25}$ -7.6 (c 1.05, CHCl₃); v_{\max} (CHCl₃)/cm⁻¹ 1200 and 1010; δ_H (270 MHz; CDCl₃) 3.56 (1 H, dd, $J_{1,6}$ 9.8), 4.21 (1 H, dd, $J_{4,5} = J_{4,3} = 9.8$), 4.40 (1 H, ddd, $J_{3,4}$ 9.8, $J_{3,P3}$ 7.6, $J_{3,2}$ 2.1), 4.60 (1 H, dd, $J_{2,1} = J_{2,3} = 2.1$), 4.63–5.23 (18 H, complex, benzylic protons and 5 H), 5.25 (1 H, ddd, $J_{6,1} = J_{6,5} = J_{6,P6} = 9.8$), 5.41–5.57 (2 H, m) and 7.06–7.44 (27 H, complex); δ_C (67.8 MHz; CDCl₃) 68.00 (d, J 6.7), 68.10 (d, J 6.7), 68.47 (d, J 6.7), 68.75 (2 C, d, J 7.9), 68.86 (d, J 6.7), 72.30, 74.75, 75.33, 75.47, 77.32 (m), 78.00 (2 C), 78.05 (m), 79.50 (m), 127.31, 127.44, 127.57, 127.69, 128.04, 128.10, 128.18, 128.22, 128.29, 128.44, 128.56, 128.59, 128.71, 128.81, 128.84, 128.98, 129.11, 134.46, 134.84, 135.12, 135.14, 135.18, 137.30, 137.64 and 138.04; δ_p (109 MHz; CHCl₃) -1.28, -0.30 and 0.48.

1D-*myo*-Inositol 1,4,5-tris(dihydrogen phosphate) 1.—(a) *Ammonium salt of 1 from phosphoranilide 12a.* To a solution of phosphoranilide 12a (526 mg, 0.461 mmol) in a 1:1:1 mixture of acetic anhydride-acetic acid-pyridine (10 cm³) was added isoamyl nitrite (2.8 cm³, 20.74 mmol) and the mixture was stirred at room temperature for two days. After water had been added, volatile materials were removed under reduced pressure at below 25 °C. A triethylammonium carbonate buffer solution of the residue was passed through a plug of DEAE-Sephadex A-25 (Pharmacia) and the column was washed with the same buffer solution. The combined eluates were concentrated to dryness under reduced pressure. The residue (318 mg) was shown to be impure on TLC (cellulose) but without further purification a solution of the mixture in methanol-water (4:1; 15 cm³) were stirred with 5% Pd-C (1.0 g) under hydrogen at room temperature overnight. After filtration to remove the catalyst, the filtrate was concentrated to dryness and the residue was subjected to column chromatography with application of pressure (cellulose). First, a solvent system of 7:2:1 propan-1-ol-28% NH₄OH-water was used as eluent and the 4,5-cyclic pyrophosphate 31, with the higher-value R_f [0.43; cellulose; 28% NH₄OH propan-1-ol-water (5.5:5:1)], was eluted (43.8 mg, ~20%). After that, the proportions of the solvents were changed to 5:4:1 and *D*-*myo*-inositol 1,4,5-tris(dihydrogen phosphate) ammonium salt was obtained (36.5 mg, 17% yield from 12a), R_f [cellulose; 28% NH₄OH-propan-1-ol-water 5.5:5:1] 0.21.

1 (ammonium salt): (Found: C, 13.7; H, 5.7; N, 9.3. C₆H₁₅O₁₅P₃(NH₃)_{3.5}(H₂O)_{2.5} requires C, 13.73; H, 5.86; N, 9.34%); $[\alpha]_D^{25}$ -10.3 (c 1.80, water, pH 6.73); δ_H [400 MHz; 12 mg in D₂O (0.4 cm³); pD ~6] 3.55 (1 H, dd, $J_{3,4}$ 8.7, $J_{3,2}$ 3.1), 3.76 (1 H, dd, $J_{6,1} = J_{6,5} = 8.7$), 3.83–3.89 (2 H, complex), 4.08–4.15 (2 H, complex). The latter complex regions which contained 1-, 2-, 4- and 5-H were disclosed mainly by *J*-resolved 2D NMR experiments as follows: δ 3.85 (1 H, ddd, $J_{5,4} = J_{5,6} = J_{5,P5} = 8.7$), 3.85 (1 H, ddd, $J_{1,6} = J_{1,P1} = 8.7$, $J_{1,2}$ 3.1), 4.10 (1 H, ddd, $J_{4,3} = J_{4,5} = J_{4,P4} = 8.7$) and 4.12 (1 H, dd, $J_{2,1} = J_{2,3} = 3.1$); δ_C [100.4 MHz; 12 mg in D₂O (0.4 cm³); pD ~6] 71.22 (C-3), 71.29 (C-2), 71.86 (m, C-6), 75.64 (d, J 5.3, C-1), 77.11 (m, C-4) and 78.75 (m, C-5); δ_p [109 MHz; 12 mg in D₂O (2.5 cm³); pD 6.73] 1.28, 2.30 and 3.23; δ_p [109 MHz; 12 mg in D₂O (2.5 cm³); pD 6.73] 1.28, 2.30 and 3.23; δ_p [109 MHz; 12 mg in D₂O (2.5 cm³); pD 11.82, NH₄OH added] 3.64, 5.41 and 5.53.

Compound 31 δ_H [400 MHz, 18 mg in D₂O (0.4 cm³)] 3.80 (1 H, dd, $J_{3,4}$ 9.9, $J_{3,2}$ 2.9), 3.95 (1 H, dd, $J_{6,1} = J_{6,5} = 9.9$), 4.05 (1 H, ddd, $J_{1,6} = J_{1,P1} = 9.9$, $J_{1,2}$ 2.9), 4.14 (1 H, ddd, $J_{5,4} = J_{5,6} = 9.9$, $J_{5,P5}$ 6.2), 4.32 (1 H, ddd, $J_{2,1} = J_{2,3} = 2.9$, $J_{2,P2}$ 1.1) and 4.42 (1 H, ddd, $J_{4,3} = J_{4,5} = 9.7$, $J_{4,P4}$ 5.9); δ_C [100.4

MHz; 18 mg in D₂O (0.4 cm³) 69.57 (d, *J* 7.6), 70.61 (t, *J* 6.5), 71.48, 75.38 (m), 78.74 (d, *J* 6.9) and 79.87 (d, *J* 6.9); δ_p[161.7 MHz, 18 mg in D₂O (~1.5 cm³); pD 6.73] -9.02 (d, *J*_{P4,P5} 17.5), -8.65 (d, *J*_{P4,P5} 17.5) and 2.52.

(b) *Sodium salt of 1 from dibenzyl phosphate derivative 12b.* A mixture of 1L-1,2,4-tri-*O*-benzyl-3,5,6-tris-*O*-(dibenzoyloxyphosphoryl)-*myo*-inositol **12b** (1.96 g, 1.48 mmol), ammonium acetate (1.0 g), and 5% Pd-C (2.0 g) in MeOH-water (4:1, 50 cm³) was stirred under hydrogen for 16 h and the catalyst was filtered off and washed with water. The combined aq. solution was evaporated below 40 °C and evaporation of aq. solutions of the residue were repeated in order to remove some of the ammonium acetate and then subjected to column chromatography on cellulose (80 g) by using, firstly, a solvent system of propan-1-ol-28% NH₄OH-water (7:2:1) (When ammonium formate was used this procedure was not necessary, because it was removed during evaporation of the filtrate) and, after elution of remaining ammonium acetate, propan-1-ol-28% NH₄OH-water (5:4:1). The eluted fractions containing InsP₃ **1** were concentrated to dryness under reduced pressure and the residue was passed successively through cation-exchange (Dowex-50) columns of H⁺-, pyridinium-, and then Na⁺-form. The sodium salt of compound **1** thus obtained was finally dried by application of heat (below 40 °C) under reduced pressure (0.1 mmHg) to afford *crystalline 1 sodium salt* quantitatively, m.p. >270 °C (Found: C, 13.9; H, 3.3. C₆H₁₂O₁₅P₃Na₃(H₂O)_{1.5} requires C, 14.05; H, 2.95%); [α]_D²³ -11.1 (*c* 0.9, water, pH 6.9); δ_H [270 MHz, 12.6 mg in D₂O (0.56 cm³); pD 6.8] 3.66 (1 H, dd, *J*_{3,4} 9.3, *J*_{3,2} 2.7), 3.85 (1 H, dd, *J*_{6,1} = *J*_{6,5} = 9.3), 3.97 (1 H, ddd, *J*_{1,6} = *J*_{1,P1} = 9.3, *J*_{1,2} unreadable), 3.99 (1 H, ddd, *J*_{5,4} = *J*_{5,6} = *J*_{5,P5} 9.3), 4.22 (1 H, dd, *J*_{2,1} = *J*_{2,3} = 2.7) and 4.25 (1 H, ddd, *J*_{4,3} = *J*_{4,5} = *J*_{4,P4} 9.3); δ_C [67.8 MHz, 12.6 mg in D₂O (0.56 cm³); pD 6.8] 70.81 (C-3), 71.15 (C-2), 71.44 (m, C-6), 75.63 (d, *J* 6.1, C-1), 77.35 (m, C-4) and 78.73 (m, C-5).

(c) *Potassium salt of 1 from o-xylene phosphate derivative 12c.* 1,4,5-Tris(*o*-xylylenedioxyphosphoryl)-*myo*-inositol **12c** (1.91 g, 1.918 mmol), 5% Pd-C (2.1 g), and 80% aq. methanol (100 cm³) were stirred together for 24 h at room temperature under hydrogen. After filtration of the catalyst and addition of pyridine to the filtrate, the aq. solution was concentrated to a small volume which was then subjected to cation-exchange chromatography of Dowex-50 (K⁺-form) and elution with water. The resulting eluate and washings were concentrated to dryness by using, firstly, a rotary evaporator under reduced pressure (~15 mmHg) below 40 °C and then at vacuum-pump pressure (~0.1 mmHg) at the same temperature to give **1 tri (potassium) salt hemihydrate** (1.02 g, quantitative yield) as a crystalline solid [Found: C, 13.4; H, 2.85. C₆H₁₂O₁₅P₃K₃(H₂O)_{0.5} requires C, 13.26; H, 2.41%]; [α]_D²³ -9.4 (*c* 1.27, water; pH 6.9); [α]_D²³ -25.2 (*c* 1.03, water; pH 10.6 adjusted by addition of cyclohexylamine); δ_H [270 MHz, 10 mg in (0.7 cm³); pD 6.1] 3.60 (1 H, dd, *J*_{3,4} 9.4, *J*_{3,2} 2.7), 3.78 (1 H, dd, *J*_{6,1} = *J*_{6,5} = 9.4), 3.89 (1 H, complex), 3.91 (1 H, ddd, *J*_{5,4} = *J*_{5,6} = *J*_{5,P5} = 9.4), 4.14 (1 H, dd, *J*_{2,1} = *J*_{2,3} = 2.7) and 4.16 (1 H, ddd, *J*_{4,3} = *J*_{4,5} = *J*_{4,P4} = 9.4).

Acknowledgements

We thank Dr. Masato Hirata of Kyushu University for biological evaluation of the synthetic Ins(1,4,5)P₃.

References

- H. Streb, R. F. Irvine, M. J. Berridge and I. Schulz, *Nature (London)*, 1983, **306**, 67. See also: M. J. Berridge and R. F. Irvine, *Nature (London)*, 1984, **312**, 315.
- R. F. Irvine, *Biochem. Soc. Trans.*, 1987, **15**, 122; M. J. Berridge, *Annu. Rev. Biochem.*, 1987, **56**, 159; S. B. Shears, *Biochem. J.*, 1989, **260**, 313.

- S. Ozaki, Y. Watanabe, T. Ogasawara, Y. Kondo, N. Shiotani, H. Nishii and T. Matsuki, *Tetrahedron Lett.*, 1986, **27**, 3157.
- (a) A. M. Cooke, B. V. L. Potter and R. Gigg, *Tetrahedron Lett.*, 1987, **28**, 2305; (b) C. B. Reese and J. G. Ward, *Tetrahedron Lett.*, 1987, **28**, 2309; (c) J. P. Vacca, S. J. deSolms and J. R. Huff, *J. Am. Chem. Soc.*, 1987, **109**, 3478; (d) S. V. Ley and F. Sternfeld, *Tetrahedron Lett.*, 1988, **29**, 5305; (e) J. L. Meek, F. Davidson and F. W. Hobbs, Jr, *J. Am. Chem. Soc.*, 1988, **110**, 2317; (f) C. E. Dreef, R. J. Tuinman, C. J. J. Elie, G. A. van der Marel and J. H. van Boom, *Recl. Trav. Chim. Pays-Bas*, 1988, **107**, 395; (g) A. E. Stepanov, O. B. Runova, V. N. Krylova and V. I. Shvets, *Zh. Org. Khim.*, 1988, **24**, 1342; (h) Y. Watanabe, T. Ogasawara, H. Nakahira, T. Matsuki and S. Ozaki, *Tetrahedron Lett.*, 1988, **29**, 5259; (i) W. Tegge, and C. E. Ballou, *Proc. Natl. Acad. Sci. USA*, 1989, **86**, 94; (j) A. M. Cooke, N. J. Noble, S. Payne, R. Gigg and B. V. L. Potter, *J. Chem. Soc., Chem. Commun.*, 1989, 269; (k) Y.-C. Liu and C.-S. Chen, *Tetrahedron Lett.*, 1989, **30**, 1617; (l) J. P. Vacca, S. J. deSolms, J. R. Huff, D. C. Billington, R. Baker, J. J. Kulagowski and I. M. Mawer, *Tetrahedron*, 1989, **45**, 5679; (m) A. E. Stepanov, O. B. Runova, G. Schlewier, B. Spiess and V. I. Shvets, *Tetrahedron Lett.*, 1989, **30**, 5125; (n) J. R. Falck and P. Yadagiri, *J. Org. Chem.*, 1989, **54**, 5851; (o) H. A. J. Carless and K. Busia, *Tetrahedron Lett.*, 1990, **31**, 3449; (p) S. V. Ley, M. Parra, A. J. Redgrave and F. Sternfeld, *Tetrahedron*, 1990, **46**, 4995.
- P. J. Garegg, T. Iversen, R. Johansson and B. Lindberg, *Carbohydr. Res.*, 1984, **130**, 322.
- S. J. Angyal, G. C. Irving, D. Rutherford and M. E. Tate, *J. Chem. Soc.*, 1965, 6662.
- J. G. Molotkovsky and L. D. Bergelson, *Tetrahedron Lett.*, 1971, 4791; Y. I. Sibrikov, A. E. Stepanov and V. I. Shvets, *Zh. Org. Khim.*, 1984, **20**, 979; P. J. Garegg, B. Lindberg, I. Kvarnström and S. C. T. Svensson, *Carbohydr. Res.*, 1985, **139**, 209; G. Baudin, B. I. Glänzer, K. S. Swaminathan and A. Vasella, *Helv. Chim. Acta*, 1988, **71**, 1367; M. Jones, K. K. Rana, J. G. Ward and R. C. Young, *Tetrahedron Lett.*, 1989, **30**, 5353. See also ref. 4k.
- (a) V. I. Shvets, B. A. Klyashchitskii, A. E. Stepanov and R. P. Evstigneeva, *Tetrahedron*, 1973, **29**, 331; (b) T. Desai, A. F. Mayoralas, J. Gigg, R. Gigg and S. Payne, *Carbohydr. Res.*, 1990, **205**, 105 and references cited therein.
- (a) Y. Watanabe, T. Matsuki and S. Ozaki, unpublished results; (b) Y. Watanabe, T. Ogasawara, N. Shiotani and S. Ozaki, *Tetrahedron Lett.*, 1987, **28**, 2607; (c) S. Ozaki, Y. Kondo, H. Nakahira, S. Yamaoka and Y. Watanabe, *Tetrahedron Lett.*, 1987, **28**, 4691; (d) S. Ozaki, M. Kohno, H. Nakahira, M. Bunya and Y. Watanabe, *Chem. Lett.*, 1988, 77; (e) Y. Watanabe, M. Mitani, T. Morita and S. Ozaki, *J. Chem. Soc., Chem. Commun.*, 1989, 482.
- S. V. Ley and F. Sternfeld, *Tetrahedron*, 1989, **45**, 3463.
- J. Gigg, R. Gigg, S. Payne and R. Conant, *J. Chem. Soc., Perkin Trans. 1*, 1987, 1757.
- D. C. Billington, R. Baker, J. J. Kulagowski and I. M. Mawer, *J. Chem. Soc., Chem. Commun.*, 1987, 314.
- E. J. Corey and W. J. Suggs, *J. Org. Chem.*, 1973, **38**, 3224.
- R. Gigg and C. D. Warren, *J. Chem. Soc. C*, 1969, 2367.
- R. Boss and R. Scheffold, *Angew. Chem., Int. Ed. Engl.*, 1976, **15**, 558.
- J. Gigg, R. Gigg, S. Payne and R. Conant, *Carbohydr. Res.*, 1985, **140**, cl.
- K. Sato, S. Sakuma, S. Muramatsu and M. Bokura, *Chem. Lett.*, 1991, 1473.
- (a) G. L. Kilgour and C. E. Ballou, *J. Am. Chem. Soc.*, 1958, **80**, 3956; (b) S. J. Angyal, M. E. Tate and S. D. Gero, *J. Chem. Soc.*, 1961, 4116; (c) V. N. Krylova, N. P. Gornaeva, G. F. Oleinik and V. I. Shvets, *Zh. Org. Khim.*, 1980, **16**, 315.
- F. Zetzsche and W. Büttiker, *Ber. Dtsch. Chem. Ges.*, 1940, **73**, 47.
- V. N. Krylova, A. I. Lyutik, N. P. Gornaeva and V. I. Shvets, *Zh. Obshch. Khim.*, 1981, **51**, 210.
- F. H. Westheimer, *Acc. Chem. Res.*, 1968, **1**, 70.
- H. G. Khorana and A. R. Todd, *J. Chem. Soc.*, 1953, 2257.
- Y. Watanabe and T. Mukaiyama, *Chem. Lett.*, 1979, 389; M. Inage, H. Chaki, S. Kusumoto and T. Shiba, *Chem. Lett.*, 1982, 1281; Y. Hayakawa, Y. Aso, M. Uchiyama and R. Noyori, *Tetrahedron Lett.*, 1983, **24**, 1165 and references cited therein.
- P. M. Chouinard and P. A. Bartlett, *J. Org. Chem.*, 1986, **51**, 75.
- Y. Watanabe, H. Nakahira, M. Bunya and S. Ozaki, *Tetrahedron Lett.*, 1987, **28**, 4179.
- D. C. Billington and R. Baker, *J. Chem. Soc., Chem. Commun.*, 1987, 1011; D. C. Billington, R. Baker, J. J. Kulagowski, I. M. Mawer, J. P. Vacca, S. J. deSolms and J. R. Huff, *J. Chem. Soc., Perkin Trans. 1*, 1989, 1423.
- S. J. deSolms, J. P. Vacca and J. R. Huff, *Tetrahedron Lett.*, 1987, **28**, 4503.

- 28 D. C. Billington, *Chem. Soc. Rev.*, 1989, **18**, 83; B. V. L. Potter, *Nat. Prod. Rep.*, 1990, **7**, 1.
- 29 M. R. Hamblin, B. V. L. Potter and R. Gigg, *J. Chem. Soc., Chem. Commun.*, 1987, 626; K.-L. Yu and B. Fraser-Reid, *Tetrahedron Lett.*, 1988, **29**, 979.
- 30 Y. Watanabe, Y. Komoda, K. Ebisuya and S. Ozaki, *Tetrahedron Lett.*, 1990, **31**, 255.
- 31 M. Sekine and T. Hata, *Tetrahedron Lett.*, 1983, **24**, 5741.
- 32 S. Kanodia and M. F. Roberts, *Proc. Natl. Acad. Sci. USA*, 1983, **80**, 5217; N. J. Noble and B. V. L. Potter, *J. Chem. Soc., Chem. Commun.*, 1989, 1194.
- 33 G. W. Mayr and W. Dietrich, *FEBS Lett.*, 1987, **213**, 278.
- 34 J. C. Lindon, D. J. Baker, R. D. Farrant and J. M. Williams, *Biochem. J.*, 1986, **233**, 275; S. Cerdan, C. A. Hansen, R. Johanson, T. Inubushi and J. R. Williamson, *J. Biol. Chem.*, 1986, **261**, 14676.
- 35 C. Jiang and D. C. J. Baker, *Carbohydr. Chem.*, 1986, **5**, 615.
- 36 A. I. Lyutik, V. N. Krylova, S. P. Kozolova, B. A. Klyashchitskii, V. I. Shvets, R. P. Evstigneeva and E. S. Zhdanovich, *Zh. Obshch. Khim.*, 1971, **41**, 2747.
- 37 J. Gigg, R. Gigg, S. Payne and R. Conant, *J. Chem. Soc., Perkin Trans. 1*, 1987, 423.

Paper 1/02021H

Received 30th April 1991

Accepted 12th November 1991